

111703

18384  
U.S. PTOAnticipated Classification  
of this Application:  
Class \_\_\_\_\_ Subclass \_\_\_\_\_Prior Application:  
Examiner J.M. Ford  
Group Art Unit 1624Attorney's  
Docket  
N .62815-A-PCT-US/  
JPW/GJG/ACKHONORABLE ASSISTANT COMMISSIONER FOR PATENTS  
Washington, D.C. 20231

November 17, 2003

22386 U.S. PTO  
10/716098  
111703

S I R:

This is a request for filing a X CONTINUATION       DIVISIONAL        CONTINUATION-IN-PART application underX 37 C.F.R. §1.53(b)        37 C.F.R. §1.53(d), of pending prior applicationSerial No. 09/355,534 filed on July 29, 1999 ofDouglas J. M. Allen, Timothy Norris, Jeffrey W. Raggon, Paul Santafianos and        for  
Inventor(s)        Ravi M. ShankerN-(3-ETHYNYLPHENYL)-6,7-BIS(2-METHOXYETHOXY)-4-QUINAZOLINAMINE MESYLATE ANHYDRATE AND  
Title of Invention        MONOHYDRATE

1. X Enclosed is a copy of the prior application, as originally filed and an affidavit or declaration verifying it as a true copy.
2.        A verified statement to establish small entity status under 37 C.F.R. §1.9 and 1.27  
       is enclosed.  
       was filed in the prior application and such status is still proper and desired (37 C.F.R. §1.28(a)).
3. X The filing fee is calculated as follows:

CLAIMS AS FILED, LESS ANY CLAIMS CANCELLED BY AMENDMENT

	NUMBER FILED		NUMBER EXTRA*		RATE		FEE	
					SMALL ENTITY	OTHER ENTITY	SMALL ENTITY	OTHER ENTITY
Total Claims	14-20	=	0	X	9	18	= \$ 0	\$ 0
Independent Claims	1-3	=	0	X	43	86	= \$ 0	\$ 0
Multiple Dependent Claims Presented: <u>      </u> Yes <u>X</u> No					145	290	= \$ 0	\$ 0
If the difference in Col. 1 is less than zero, enter "0" in Col. 2.					BASIC FEE		\$ 385	\$ 770
					TOTAL FEE		\$	\$ 770

Filing an application pursuant to this section expressly abandons the parent application.

Cont.Div.  
Page 2

4.   X   Th Commissioner is hereby authorized to charg payment of the following fees associated with this application or credit any overpayment to Deposit Account No. 03-3125.
- X   Any additional filing fees required under 37 C.F.R. §1.16.
- X   Any patent application processing fees under 37 C.F.R. §1.17.
- The issue fees set forth in 37 C.F.R. §1.18 at or before mailing of the Notice of Allowance, pursuant to 37 C.F.R. §1.311(b).
5.   X   Three copies of this sheet are enclosed.
6.   X   A check in the amount of \$ 770.00 is enclosed.
7.        Cancel claims                                 .
8.        Amend the specification by inserting before the first line the sentence: --This is a        continuation        division of application Serial No.                         , filed                         ---
9.               Sheet(s) of        informal        formal drawing(s) is/ are enclosed.
10.        Transfer the drawings from the prior application to this application and abandon said prior application as of the filing date accorded this application. A duplicate copy of this sheet is enclosed for filing in the prior application file.
11.        Priority of application No.                          filed on                          in                          (country) is claimed under 37 U.S.C. §119.
- The certified copy of the priority application has been filed in prior application Serial No.                         , filed                         .
12.   X   The prior application is assigned of record to OSI Pharmaceuticals, Inc.
13.   X   A preliminary amendment is enclosed, including Information Disclosure Statement.
14.   X   The power of attorney in the prior application is to:

John P. White (Reg. No. 28,678); Christopher C. Dunham (Reg. No. 22,031); Norman H. Zivin (Reg. No. 25,385); Jay H. Maioli (Reg. No. 27,213); William E. Pelton (Reg. No. 25,702); Robert D. Katz (Reg. No. 30,141); Peter J. Phillips (Reg. No. 29,691); Wendy E. Miller (Reg. No. 35,615); Richard S. Milner (Reg. No. 33,970); Robert T. Maldonado (Reg. No. 38,232); Paul Teng (Reg. N . 40,837); Richard F. Jaworski (Reg. No. 33,515); Alan J. Morrison (Reg. No. 37,399); Mark A. Farley (Reg. No. 33,170); Pedro C. Fernandez (Reg. No. 41,741); Gary J. Gershik (Reg. No. 39,992); and Christine S. Nickles (Reg. No. 51,103)

Cont/Div.  
Page 3

- (a) \_\_\_\_\_ The power appears in the original papers in the prior application.
- (b) X Since the power does not appear in the original papers, a copy of the power in the prior application is enclosed.
- (c) X Address all future communications to:  
(May only be completed by applicant, or attorney or agent of record.)

John P. White

Cooper & Dunham LLP

1185 Avenue of the Americas

New York, New York 10036

15. X Also enclosed Express Mail Certificate of Mailing No.  
EV 325 703 326 US, dated November 17, 2003

16. \_\_\_\_\_ I hereby verify that the attached papers are a true copy of prior application Serial No. \_\_\_\_\_ as originally filed on \_\_\_\_\_.

The undersigned declares further that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statement and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

November 17, 2003

Date

Signature

Gary J. Gershik  
John P. White, Reg. No. 28,678  
Gary J. Gershik, Reg. No. 39,992

\_\_\_\_\_  
INVENTOR(S)

\_\_\_\_\_  
ASSIGNEE OF COMPLETE INTEREST

X ATTORNEY OR AGENT OF RECORD

\_\_\_\_\_  
FILED UNDER 37 C.F.R. §1.34(a)

Address of Signator:

John P. White, Esq.  
Cooper & Dunham LLP

1185 Avenue of the Americas

New York, New York 10036

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: Douglas J. M. Allen et al.  
Serial No.: Not Yet Known (a continuation of U.S. Serial No.  
09/355,534, filed July 29, 1999)  
Filed : Herewith  
Title : N-(3-ETHYNYLPHENYL)-6,7-BIS(2-METHOXYETHOXY)-  
4-QUINAZOLINAMINE MESYLATE ANHYDRATE AND  
MONOHYDRATE


1185 Avenue of the Americas  
New York, New York 10036  
November 17, 2003

Mail Stop Patent Application  
Commissioner For Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


SIR:

**EXPRESS MAIL CERTIFICATE OF MAILING**  
**FOR ABOVE-IDENTIFIED APPLICATION**

"Express Mail" mailing label number: EV 325 703 326 US  
Date of Deposit: November 17, 2003  
I hereby certify that this paper or fee is being deposited to the  
United States Postal Service "Express Mail Post Office to  
Addressee" service under 37 C.F.R. §1.10 on the date indicated  
above and is addressed to the Commissioner for Patents, P.O. Box  
1450, Alexandria, VA 22313-1450:

  
Printed Name: John P. White

Respectfully submitted,

  
John P. White  
Registration No. 28,678  
Gary J. Gershik  
Registration No. 39,992  
Attorneys for Applicants  
Cooper & Dunham LLP  
1185 Avenue of the Americas  
New York, New York 10036  
Tel (212) 278-0400

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants : Douglas J. M. Allen et al.  
Serial No. : 09/355,534 Art Unit: 1624  
Filed : July 29, 1999 Examiner: J. Ford  
For : N-(3-ETHYNYLPHENYLAMINO)-6, 7-BIS (2-METHOXYETHOXY)-4-QUINAZOLINAMINE MESYLATE ANHYDRATE AND MONOHYDRATE

1185 Avenue Of The Americas  
New York, New York 10036

Assistant Commissioner for Patents  
Washington, D.C. 20231

SIR:

**ASSOCIATE POWER OF ATTORNEY AND NOTICE OF CHANGE OF ADDRESS**

Please recognize John P. White (Registration No. 28,678) and Gary J. Gershik (Registration No. 39,992) as associate attorneys in the above-identified application and direct all correspondence to:

John P. White, Esq.  
Cooper & Dunham LLP  
1185 Avenue of the Americas  
New York, New York 10036

Respectfully submitted,



Bryan C. Zielinski  
Registration No. 34,462  
Attorney for Applicants

Pfizer, Inc.  
Patent Dept., 20<sup>th</sup> Floor  
235 East 42<sup>nd</sup> Street  
New York, NY 10017-5755  
(212)573-4585